SOURCE: GlobeImmune, Inc.

January 03, 2008 07:00 ET

GlobeImmune to Present at the JPMorgan Healthcare Conference

LOUISVILLE, CO--(Marketwire - January 3, 2008) - GlobeImmune, Inc. announced today that President and Chief Executive Officer, Timothy C. Rodell, M.D., will present at the JPMorgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco on Tuesday, January 8, 2008 at 8:30 a.m. PST in the Elizabethan C/D Room.

GlobeImmune is a private Colorado-based company developing proprietary yeast-based therapeutics called Tarmogens for the treatment of cancer and infectious diseases. The Company's infectious disease product candidate, GI-5005, has completed a Phase 1b clinical trial and is currently being evaluated in a randomized Phase 2 trial in patients with chronic hepatitis C infection. The Company's lead oncology product, GI-4000, is being evaluated in a randomized, placebo-controlled Phase 2 trial in patients with resectable pancreas cancer in combination with adjuvant gemcitabine.

For additional information, please visit the company's website at www.globeimmune.com.

The anticipated presentation will contain forward-looking statements that involve significant risks and uncertainties, including statements relating to the efficacy of the Company's technology and initiation, progress, and results of the Company's clinical trial programs. Actual results could differ materially from those projected and the Company cautions readers not to place undue reliance on the forward-looking statements contained in the presentation.